-
Industry: In the long run, the pharmaceutical industry is still a "long slope and thick snow" track
Time of Update: 2022-05-11
Specifically, the The fund manager believes that there are many investment opportunities in the field of innovative drugs and medical devices, because innovative products have strong explosive performance and are supported by logic such as independent innovation and import substitution .
-
Head biotechs with good business continue to be optimistic about maintaining the "overweight" rating of these pharmaceutical companies
Time of Update: 2022-05-11
In addition, Keji Pharmaceutical has continued to increase investment in research and development, which has laid a solid foundation for its technical strength in the industry .
-
Industry: The "bubble" of innovative drugs will burst, and a large number of Biotech companies may disappear!
Time of Update: 2022-05-11
[Pharmaceutical Network Market Analysis] In recent years, with the continuous introduction of domestic policies to support pharmaceutical innovation, China's innovative drug industry has ushered in r
-
The R&D expenses of thousands of companies have increased by more than 20%, and the pharmaceutical and biological fields account for a large proportion
Time of Update: 2022-05-11
In recent years, with the country's continuous emphasis on innovative drugs, pharmaceutical companies have begun to increase investment in research and development to achieve transformation .
-
Innovative drugs enter the harvest period, tracking the development of innovative drugs in Q2 in 2022
Time of Update: 2022-05-10
On the innovative research and development track of PD-1, a new drug for the treatment of tumors, the competition of domestic innovative pharmaceutical companies has gradually shifted to overseas markets.
-
To promote the high-quality development of the Chinese herbal medicine industry, how should pharmaceutical machine companies provide efficient "assistance"?
Time of Update: 2022-05-10
With the high-quality development of the Chinese herbal medicine industry, pharmaceutical machine companies will play an important role in strengthening the quality supervision of Chinese medicine products and ensuring the safety of public medication.
-
Domestic PD-1 has fallen into a wave of price cuts, and overseas markets have become a new battlefield
Time of Update: 2022-05-10
In this context, in order to avoid homogenization and low-price competition and obtain more development opportunities, domestic innovative pharmaceutical companies have begun to set their sights on overseas markets .
-
In the 100 billion medical device market, many companies have entered the market
Time of Update: 2022-05-10
[Pharmaceutical Network Market Analysis] In recent years, China's medical device industry is maintaining steady growth .
With the continuous development of the economic level and the increasing demand for health, China's medical device market will undoubtedly usher in huge development opportunities .
-
Boost market confidence!
Time of Update: 2022-05-10
According to statistics, 102 companies in Hong Kong stocks have repurchased since this year, and from the industry distribution of repurchasing companies, the pharmaceutical industry accounts for a large proportion, with a total of 20 companies .
-
With the advent of new drugs and drug price cuts, breast cancer treatment has accelerated into a new era!
Time of Update: 2022-05-10
In recent years, with the continuous development and application of anti-HER2 drugs, the treatment of HER2-positive breast cancer patients has been improved to some extent .
-
Since April, many pharmaceutical companies have achieved IPOs
Time of Update: 2022-05-09
48 billion yuan, which will be used for next-generation product research and development projects, high-end medical imaging equipment industrialization fund projects, marketing service network projects, informatization improvement projects, and supplementary working capital .
-
New pharmaceutical stocks set off a "breaking wave" again!
Time of Update: 2022-05-09
On April 12, the first trading day of the listing of Haichuang Pharmaceutical, a new stock on the Science and Technology Innovation Board, broke at the opening.
-
The personnel adjustment and changes of multinational pharmaceutical companies are frequent, and the industry believes that this is the reason
Time of Update: 2022-05-09
Since April this year, a number of multinational pharmaceutical companies have announced major personnel changes, involving presidents and vice presidents .
Vice President, currently head of the Oncology Strategy Business Unit at Bayer Pharma .
-
License in is still a major means for local pharmaceutical companies to deploy innovative drugs
Time of Update: 2022-05-09
[Pharmaceutical Network Market Analysis] On April 25, Chia Tai Tianqing announced that the company and Anyuan Pharmaceutical have reached a strategic cooperation on the rights development and commercialization of the latter's two innovative drugs AP025 and AP026 in China and some Asian regions.
-
Centralized procurement and heavy volume have become the highlights of the 2021 annual reports of some "barefoot" pharmaceutical companies
Time of Update: 2022-05-09
In addition, in the first quarter of 2022, the company's performance continued to grow, achieving operating income of 517 million yuan, a year-on-year increase of 42.
The annual report data shows that in the fourth quarter of 2021, the company's operating income reached 689 million yuan, a year-on-year increase of 114.
-
Industry: Over 1,000 biopharmaceutical companies will disappear in 2022
Time of Update: 2022-05-09
In July 2021, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration issued a notice on the public solicitation of opinions on the "Guiding Principles for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Value", requiring that new drug research and development "focus on patient needs, Guided by clinical value”, referring to the current domestic innovative drug targets, the proliferation of “Me-too” (similar to innovative drugs), low-level repetition, and lack of real innovation .
-
Policies continue to benefit the traditional Chinese medicine industry. How to grasp the main line of future development?
Time of Update: 2022-05-09
In addition, traditional Chinese medicine should also adhere to theoretical innovation, clinical services to improve efficacy, effective formulation of prescriptions to transform new drugs, and promotion of industrial development, and then to international development, in order to achieve the modernization, industrialization, internationalization and high-quality development of the traditional Chinese medicine industry .
-
CXO is still a track with strong performance growth and certainty in the pharmaceutical sector
Time of Update: 2022-05-09
It is reported that Asymchem and Proton have successively obtained large orders from multinational pharmaceutical companies; the orders in hand of Zhaoyan New Drug and Tigermed have hit a record high; WuXi Biologics is also actively developing emerging businesses such as vaccines and ADC drugs CDMO.
-
From 2022 to 2030, the scale of my country's antibacterial drug market may show a trend of first increase and then decrease
Time of Update: 2022-05-09
Data show that from 2016 to 2019, the scale of China's antimicrobial drug market showed a slow growth trend .
It is predicted that from 2022 to 2030, the scale of China's antimicrobial drug market may show a trend of first rising and then falling .
-
Innovative pharmaceutical equipment continues to survive the fittest, and it is recommended to pay attention to these companies in the field of pharmaceutical equipment
Time of Update: 2022-05-09
For upstream pharmaceutical equipment, reagents, consumables and other fields, analysts suggest to pay attention to Tofflon, Chutian Technology, Tailin Bio and other companies .
